CYTHW
Income statement / Annual
Last year (2023), Cyclo Therapeutics, Inc.'s total revenue was $1.08 M,
a decrease of 21.76% from the previous year.
In 2023, Cyclo Therapeutics, Inc.'s net income was -$20.06 M.
See Cyclo Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$1.08 M |
$1.38 M |
$1.59 M |
$903.38 K |
$1.01 M |
$1.01 M |
$1.24 M |
$1.50 M |
$950.46 K |
$1.57 M |
| Cost of Revenue |
$98.46 K
|
$138.93 K
|
$156.08 K
|
$66.40 K
|
$75.49 K
|
$105.03 K
|
$132.92 K
|
$198.43 K
|
$124.43 K
|
$272.64 K
|
| Gross Profit |
$977.95 K
|
$1.24 M
|
$1.43 M
|
$836.98 K
|
$931.71 K
|
$906.45 K
|
$1.10 M
|
$1.30 M
|
$826.03 K
|
$1.29 M
|
| Gross Profit Ratio |
0.91
|
0.9
|
0.9
|
0.93
|
0.93
|
0.9
|
0.89
|
0.87
|
0.87
|
0.83
|
| Research and Development Expenses |
$14.18 M
|
$9.00 M
|
$9.15 M
|
$6.10 M
|
$4.87 M
|
$2.71 M
|
$2.29 M
|
$1.86 M
|
$658.51 K
|
$94.13 K
|
| General & Administrative Expenses |
$5.66 M
|
$7.81 M
|
$6.50 M
|
$3.68 M
|
$3.43 M
|
$2.43 M
|
$2.62 M
|
$2.64 M
|
$2.22 M
|
$1.53 M
|
| Selling & Marketing Expenses |
$3.90 K
|
$13.06 K
|
$18.34 K
|
$5.01 K
|
$5.89 K
|
$5.64 K
|
$7.85 K
|
$7.16 K
|
$7.57 K
|
$10.90 K
|
| Selling, General & Administrative Expenses |
$6.83 M
|
$7.82 M
|
$6.52 M
|
$3.68 M
|
$3.44 M
|
$2.44 M
|
$2.63 M
|
$2.65 M
|
$2.23 M
|
$1.55 M
|
| Other Expenses |
$0.00
|
$30.50 K
|
$27.54 K
|
$19.95 K
|
$13.98 K
|
$13.95 K
|
$19.77 K
|
$130.95 K
|
$202.02 K
|
$217.52 K
|
| Operating Expenses |
$21.04 M
|
$16.85 M
|
$15.70 M
|
$9.80 M
|
$8.32 M
|
$5.16 M
|
$4.95 M
|
$4.65 M
|
$3.09 M
|
$1.86 M
|
| Cost And Expenses |
$21.13 M
|
$16.99 M
|
$15.85 M
|
$9.86 M
|
$8.40 M
|
$5.27 M
|
$5.08 M
|
$4.85 M
|
$3.22 M
|
$2.13 M
|
| Interest Income |
$0.00
|
$12.47 K
|
$3.41 K
|
$19.80 K
|
$12.03 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$28.60 K
|
$31.29 K
|
$33.67 K
|
| Depreciation & Amortization |
$19.28 K
|
$19.48 K
|
$16.83 K
|
$12.76 K
|
$5.68 K
|
$10.12 K
|
$9.27 K
|
$107.10 K
|
$169.03 K
|
$152.45 K
|
| EBITDA |
-$20.03 M |
-$15.60 M |
-$14.27 M |
-$8.95 M |
-$7.39 M |
-$4.24 M |
-$3.82 M |
-$4.09 M |
-$2.23 M |
-$406.57 K |
| EBITDA Ratio |
-18.61
|
-11.34
|
-9
|
-9.91
|
-7.33
|
-4.2
|
-3.09
|
-2.72
|
-2.35
|
-0.26
|
| Operating Income Ratio |
-18.63
|
-11.35
|
-9
|
-9.92
|
-7.34
|
-4.22
|
-3.11
|
-2.8
|
-2.53
|
-0.36
|
| Total Other Income/Expenses Net |
-$7.25 K
|
$171.00 K
|
$3.41 K
|
$19.80 K
|
$12.03 K
|
$11.77 K
|
$10.26 K
|
-$17.95 K
|
-$24.62 K
|
-$30.37 K
|
| Income Before Tax |
-$20.06 M
|
-$15.45 M
|
-$14.29 M
|
-$8.94 M
|
-$7.53 M
|
-$4.26 M
|
-$3.83 M
|
-$4.22 M
|
-$2.43 M
|
-$592.69 K
|
| Income Before Tax Ratio |
-18.63
|
-11.23
|
-9.01
|
-9.9
|
-7.48
|
-4.21
|
-3.1
|
-2.81
|
-2.56
|
-0.38
|
| Income Tax Expense |
$0.00
|
-$171.00 K
|
$18.52 K
|
-$18.53 K
|
$141.75 K
|
$11.77 K
|
$0.00
|
$28.60 K
|
$120.00 K
|
$33.67 K
|
| Net Income |
-$20.06 M
|
-$15.28 M
|
-$14.31 M
|
-$8.92 M
|
-$7.67 M
|
-$4.26 M
|
-$3.83 M
|
-$4.22 M
|
-$2.55 M
|
-$592.69 K
|
| Net Income Ratio |
-18.63
|
-11.11
|
-9.02
|
-9.88
|
-7.62
|
-4.21
|
-3.1
|
-2.81
|
-2.68
|
-0.38
|
| EPS |
-1.23 |
-1.81 |
-2.25 |
-5.58 |
-7.09 |
-5.2 |
-5.32 |
-6.67 |
-4.54 |
-1.17 |
| EPS Diluted |
-1.23 |
-1.81 |
-2.25 |
-5.58 |
-7.09 |
-5.2 |
-5.32 |
-6.67 |
-4.54 |
-1.17 |
| Weighted Average Shares Out |
$16.33 M
|
$8.44 M
|
$6.37 M
|
$1.60 M
|
$1.08 M
|
$817.57 K
|
$720.37 K
|
$633.54 K
|
$562.09 K
|
$505.43 K
|
| Weighted Average Shares Out Diluted |
$16.33 M
|
$8.44 M
|
$6.37 M
|
$1.60 M
|
$1.08 M
|
$817.57 K
|
$720.37 K
|
$633.54 K
|
$562.09 K
|
$505.43 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
